News Column

Researchers from National Center for Nanoscience and Technology Discuss Findings in Liposomes (Liposomal chemotherapeutics)

August 25, 2014



By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Biotechnology. According to news reporting from Beijing, People's Republic of China, by NewsRx journalists, research stated, "Currently, six liposomal chemotherapeutics have received clinical approval and many more are in clinical trials or undergoing preclinical evaluation. Liposomes exhibit low toxicity and improve the biopharmaceutical features and therapeutic index of drugs, thereby increasing efficacy and reducing side effects."

The news correspondents obtained a quote from the research from National Center for Nanoscience and Technology, "In this review we discuss the advantages of using liposomes for the delivery of chemotherapeutics. Gemcitabine and paclitaxel have been chosen as examples to illustrate how the performance of a metabolically unstable or poorly water-soluble drug can be greatly improved by liposomal incorporation."

According to the news reporters, the research concluded: "We look at the beneficial effects of liposomes in a variety of solid and blood-borne tumors, including thyroid cancer, pancreatic cancer, breast cancer and multiple myeloma."

For more information on this research see: Liposomal chemotherapeutics. Future Oncology, 2013;9(12):1849-1859. Future Oncology can be contacted at: Future Medicine Ltd, Unitec House, 3RD Floor, 2 Albert Place, Finchley Central, London, N3 1QB, England (see also Biotechnology).

Our news journalists report that additional information may be obtained by contacting E. Gentile, Natl Center Nanosci & Technol China, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, People's Republic of China. Additional authors for this research include F. Cilurzo, L. Di Marzio, M. Carafa, C.A. Ventura, J. Wolfram, D. Paolino and C. Celia.

Keywords for this news article include: Asia, Biotechnology, Cancer, Beijing, Therapy, Oncology, Liposomes, Drug Delivery Systems, People's Republic of China

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters